Pancreatic Cancer Research

ResearcherUniversity of BernActive in the last 2 years

Eva Karamitopoulou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4833-1373; OpenAlex author ID A5044272557. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2012: 2 papers · 2013: 4 papers · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 32

  1. RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged Survival in Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.modpat.2026.101010↗
  2. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - Exploring the "Space". Last author DOI 10.1016/j.canlet.2025.217699↗
  3. Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heteroge… Last author DOI 10.1038/s41416-025-02959-w↗
  4. Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-0368↗
  5. Emerging Prognostic and Predictive Factors in Pancreatic Cancer. Co-author DOI 10.1016/j.modpat.2023.100328↗
  6. Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-35796-7↗
  7. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-329371↗
  8. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Co-author DOI 10.1016/j.ejca.2022.03.033↗
  9. SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers14040916↗
  10. Molecular Pathology of Pancreatic Cancer. Co-author DOI 10.3390/cancers14061523↗
  11. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Co-author DOI 10.1007/s00428-020-02987-2↗
  12. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Co-author DOI 10.1016/j.ctrv.2021.102208↗
  13. PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups. Co-author DOI 10.1158/2326-6066.cir-21-0144↗
  14. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer. Last author DOI 10.3389/fimmu.2021.643529↗
  15. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Co-author DOI 10.1126/sciadv.abb9200↗
  16. The Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.3390/cancers12103076↗
  17. A Multiscale Map of the Stem Cell State in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.cell.2019.03.010↗
  18. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. Co-author DOI 10.1038/s41416-019-0479-5↗
  19. Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: The Good, the Bad and the Ugly Scenario. Co-author DOI 10.3390/cancers11070968↗
  20. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system. Co-author DOI 10.1111/his.13508↗
  21. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Last author DOI 10.1158/1078-0432.ccr-17-3401↗
  22. MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. Co-author DOI 10.1038/modpathol.2017.35↗
  23. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. Last author DOI 10.1016/j.ejca.2016.06.013↗
  24. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal … Last author DOI 10.1038/bjc.2015.177↗
  25. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an inde… Last author DOI 10.18632/oncotarget.2775↗
  26. Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis. Co-author DOI 10.1177/039463201402700208↗
  27. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2012.10.022↗
  28. Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Reply to comment. Co-author DOI 10.1016/j.ejca.2013.03.028↗
  29. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic du… Co-author DOI 10.1186/1479-5876-11-311↗
  30. Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link? Co-author DOI 10.3389/fonc.2013.00221↗
  31. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Last author DOI 10.1111/j.1365-2559.2011.04121.x↗
  32. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Co-author DOI 10.3389/fonc.2012.00209↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beat Gloor · 16 shared papers, 2013–2026 · strength 2.25
  2. Aurel A. Perren · 11 shared papers, 2013–2026 · strength 1.69
  3. Martin Wartenberg · 10 shared papers, 2015–2025 · strength 1.02
  4. Anna Silvia Wenning · 4 shared papers, 2022–2026 · strength 0.97
  5. Animesh Acharjee · 4 shared papers, 2021–2026 · strength 0.91
  6. Pauline Aeschbacher · 3 shared papers, 2023–2026 · strength 0.77
  7. Konstantin Bräutigam · 2 shared papers, 2025–2026 · strength 0.66
  8. Alessandro Lugli · 7 shared papers, 2013–2025 · strength 0.62
  9. José A. Galván · 5 shared papers, 2015–2025 · strength 0.59
  10. Andréas Andreou · 2 shared papers, 2021–2022 · strength 0.36
  11. K Szymoński · 1 shared paper, 2025 · strength 0.33
  12. Erik Vassella · 3 shared papers, 2016–2018 · strength 0.21
  13. Nikki K. Lytle · 2 shared papers, 2019–2023 · strength 0.20
  14. Lesley Paige Ferguson · 2 shared papers, 2019–2023 · strength 0.20
  15. Nirakar Rajbhandari · 2 shared papers, 2019–2023 · strength 0.20
  16. Andrew M. Lowy · 2 shared papers, 2019–2023 · strength 0.20
  17. Tannishtha Reya · 2 shared papers, 2019–2023 · strength 0.20
  18. Mathias Worni · 2 shared papers, 2018 · strength 0.17
  19. Mirjam Schenk · 1 shared paper, 2021 · strength 0.15
  20. Hassan Sadozai · 1 shared paper, 2021 · strength 0.15
  21. Manuel Collado · 1 shared paper, 2022 · strength 0.13
  22. Estefanía Carrasco‐García · 1 shared paper, 2022 · strength 0.13
  23. Manuel M. Hidalgo · 1 shared paper, 2022 · strength 0.13
  24. Ander Matheu · 1 shared paper, 2022 · strength 0.13
  25. Andrea Cacciato Insilla · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.